ANAVEX LIFE SCIENCES CORP. Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Anavex Life Sciences Corp. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Anavex Life Sciences Corp. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $2.5M, a 35.9% decline year-over-year.
  • Anavex Life Sciences Corp. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $10.7M, a 44.5% decline year-over-year.
  • Anavex Life Sciences Corp. annual Share-based Payment Arrangement, Expense for 2023 was $16.4M, a 10.9% decline from 2022.
  • Anavex Life Sciences Corp. annual Share-based Payment Arrangement, Expense for 2022 was $18.4M, a 124% increase from 2021.
  • Anavex Life Sciences Corp. annual Share-based Payment Arrangement, Expense for 2021 was $8.2M, a 68.1% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $16.4M -$2M -10.9% Oct 1, 2022 Sep 30, 2023 10-K 2023-11-27
2022 $18.4M +$10.2M +124% Oct 1, 2021 Sep 30, 2022 10-K 2023-11-27
2021 $8.2M +$3.32M +68.1% Oct 1, 2020 Sep 30, 2021 10-K 2023-11-27
2020 $4.88M -$1.55M -24.2% Oct 1, 2019 Sep 30, 2020 10-K 2022-11-28
2019 $6.43M +$914K +16.6% Oct 1, 2018 Sep 30, 2019 10-K 2020-12-28
2018 $5.52M +$1.38M +33.4% Oct 1, 2017 Sep 30, 2018 10-K 2019-12-16
2017 $4.14M -$927K -18.3% Oct 1, 2016 Sep 30, 2017 10-K/A 2019-01-25
2016 $5.06M +$3.43M +210% Oct 1, 2015 Sep 30, 2016 10-K/A 2019-01-25
2015 $1.63M +$1.61M +5751% Oct 1, 2014 Sep 30, 2015 10-K 2017-12-11
2014 $27.9K Oct 1, 2013 Sep 30, 2014 10-K 2016-12-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.